Carregant...

The Value of PD-L1 Expression in Predicting the Efficacy of Anti-PD-1 or Anti-PD-L1 Therapy in Patients with Cancer: A Systematic Review and Meta-Analysis

OBJECTIVES: Recent trials have shown an overall survival (OS) benefit in 10-40% advanced cancer patients treated with programmed cell death 1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors. Here, we aimed to evaluate the relationship between PD-L1 expression and the therapeutic efficacy of P...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Dis Markers
Autors principals: Chen, Xiao-Jiang, Yuan, Shu-Qiang, Duan, Jin-Ling, Chen, Yong-Ming, Chen, Shi, Wang, Yun, Li, Yuan-Fang
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7787798/
https://ncbi.nlm.nih.gov/pubmed/33488843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/6717912
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!